Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan… | Phase 1 | terminated | Oct 1, 2018 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint… | Phase 1 | terminated | Dec 7, 2022 | SLK Kliniken Heilbronn GmbH | Premature discontinuation due to üoor participant recruitment | Enrollment / accrual |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell… | Phase 2 | terminated | Jun 11, 2018 | Roberto Pili | Funder halted development of compound in this disease | Other (stated, no rule matched) |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of…(NIVIX) | Phase 1 / Phase 2 | terminated | Aug 23, 2018 | Michelle S Ludwig | A recent change in treatment landscape may make study futile | Other (stated, no rule matched) |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who… | — | withdrawn | Oct 3, 2011 | Gynecologic Oncology Group | not stated | Not stated |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline… | Phase 2 | withdrawn | Oct 10, 2022 | AdventHealth | PI Decision based on no enrollment | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | Phase 1 | withdrawn | Feb 21, 2023 | Insel Gruppe AG, University Hospital Bern | IMP security Issues reported by Sponsor | Other (stated, no rule matched) |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have… | Phase 2 | terminated | May 29, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03905889 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Phase 1 | terminated | Apr 5, 2019 | Brown University | Funding withdrawn | Funding |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04688931 | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder…(ATLAS) | Phase 3 | terminated | Dec 30, 2020 | UroGen Pharma Ltd. | Alternate approach pursued | Other (stated, no rule matched) |
| NCT02542202 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent… | N/A | terminated | Sep 4, 2015 | University of Chicago | due to slow enrollment | Enrollment / accrual |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic…(ERICA) | Phase 2 | terminated | Jun 19, 2018 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving…(OPTIMISE) | — | terminated | May 4, 2017 | Pfizer | The study was terminated early due to the inability to recruit the planned number of patients | Enrollment / accrual |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell… | Phase 1 | terminated | Jun 12, 2020 | Abramson Cancer Center at Penn Medicine | failure to accrue | Enrollment / accrual |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or… | Phase 2 | terminated | Apr 22, 2024 | Fundacion Oncosur | The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive… | Other (stated, no rule matched) |
| NCT03915405 | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Phase 1 | terminated | Apr 16, 2019 | Kyowa Kirin, Inc. | Termination was based on the business decision | Sponsor / business decision |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT05699135 | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People… | — | terminated | Jan 26, 2023 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in… | Phase 1 | withdrawn | Jun 8, 2023 | Weill Medical College of Cornell University | Insufficient funding | Funding |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | Phase 1 / Phase 2 | terminated | Apr 29, 2009 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or… | Phase 1 / Phase 2 | terminated | Oct 16, 2013 | Fox Chase Cancer Center | Study drug is no longer supplied by grantor. | Other (stated, no rule matched) |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | May 25, 2016 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | Phase 1 | terminated | Jan 31, 2022 | Lioe-Fee de Geus-Oei, MD PhD | Reached the stop criteria after the interim analysis | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 20, 2024source: clinicaltrials